Research Topics
Species | Brian A WalkerSummaryAffiliation: Institute of Cancer Research Country: UK Publications
| Collaborators
|
Detail Information
Publications
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueBrian A Walker
Section of Haemato oncology, The Institute of Cancer Research, London, UK
Blood 116:e56-65. 2010..This study was registered at http://isrctn.org as ISRCTN68454111...- Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myelomaBrian A Walker
The Institute of Cancer Research, London, UK
Blood 117:553-62. 2011..Overall, DNA methylation changes significantly during disease progression and between cytogenetic subgroups... - Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survivalKevin D Boyd
The Institute of Cancer Research, Haemato Oncology Research Unit, Division of Molecular Pathology, London, United Kingdom
Clin Cancer Res 17:7776-84. 2011..Regions on 1p with recurrent deletions in presenting myeloma patients were examined with the purpose of defining the deletions and assessing their survival impact... 
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapyKevin D Boyd
The Institute of Cancer Research, Section of Haemato oncology, London, United Kingdom
Genes Chromosomes Cancer 50:765-74. 2011....
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcomeNicholas J Dickens
Section of Haemato oncology, The Institute of Cancer Research, London, United Kingdom
Clin Cancer Res 16:1856-64. 2010..However, these indicators do not capture all prognostic information. Gene expression analysis can be used to identify poor-prognosis patients and this can be improved by combination with information about DNA-level changes...- XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatmentsTina Bagratuni
Section of Haemato oncology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
Blood 116:250-3. 2010..This study highlights the importance of XBP1 in myeloma and its significance as an independent prognostic marker and as a predictor of thalidomide response... - Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myelomaMatthew W Jenner
Section of Haemato oncology, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
Blood 110:3291-300. 2007..These 2 genes and their corresponding pathways provide an important insight into the potential mechanisms by which 16q LOH confers poor prognosis... - Deletions of CDKN2C in multiple myeloma: biological and clinical implicationsPaola E Leone
Section of Haemato oncology, The Institute of Cancer Research, 15 Cotswold Road, London, United Kingdom
Clin Cancer Res 14:6033-41. 2008..3 has been identified in myeloma cell lines as the potential target of the deletion. We tested the clinical impact of 1p deletion and used high-resolution techniques to define the role of CDKN2C in primary patient material... - Gender disparities in the tumor genetics and clinical outcome of multiple myelomaKevin D Boyd
The Institute of Cancer Research, Section of Haemato oncology, London, United Kingdom
Cancer Epidemiol Biomarkers Prev 20:1703-7. 2011..Several cancer types have differences in incidence and clinical outcome dependent on gender, but these are not well described in myeloma. The aim of this study was to characterize gender disparities in myeloma... - Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myelomaDavid C Johnson
Institute of Cancer Research, London, UK
J Clin Oncol 29:797-804. 2011..To indentify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN)... - Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myelomaBrian A Walker
Haemato Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK
Blood 120:1077-86. 2012..These results are consistent with a distinct molecular pathogenesis underlying each subgroup and have important impacts on targeted treatment strategies. The Medical Research Council Myeloma IX trial is registered under ISRCTN68454111... - A modified method for whole exome resequencing from minimal amounts of starting DNAIwanka Kozarewa
The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
PLoS ONE 7:e32617. 2012..This method, which can be performed in most laboratories using commonly available reagents, has the potential to enhance large scale profiling efforts such as the resequencing of tumour exomes... - The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myelomaLuca Agnelli
Department of Medical Sciences, University of Milan and Hematology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Italy
Clin Cancer Res 17:7402-12. 2011....